COMMITTEE ON FEDERAL LEGISLATION

JOHN S. SIFFERT CHAIR 500 FIFTH AVENUE, FLOOR 33 NEW YORK, NY 10110 (212) 921-8399 FAX # (212) 764-3701 jsiffert@lswlaw.com

April 28, 2005

JOHN P. COLLINS, JR.

SECRETARY

300 QUARROPAS STREET, FLOOR 3

WHITE PLAINS, NY 10601

(914) 993-1919

FAX # (914) 993-1980

john.collins@usdoj.gov

VIA TELECOPIER – (202) 228-0359 <u>CONFIRMATION COPY BY MAIL</u>

The Honorable Mike Enzi Chairman Senate Committee on Health, Education, Labor & Pensions 428 Dirksen Senate Office Building Washington, D.C. 20510-6300

Re: S. 471. The Stem Cell Research Enhancement Act of 2005

Dear Senator Enzi:

We write on behalf of the Association of the Bar of the City of New York ("Association of the Bar") to express our strong support for S. 471, the Stem Cell Research Enhancement Act of 2005. S. 471 appropriately expands federal support for stem cell research beyond the current federal stem cell research program, and sets strict, but workable, standards to guard against the misuse of human embryonic materials.

Stem cell research holds enormous promise as scientists work to unravel the mysteries of human development and find cures to many devastating illnesses. According to the National Institutes of Health, human stem cells have the potential to treat patients who would now need an organ transplant, as well as those suffering from diseases including Parkinson's and Alzheimer's diseases, spinal cord injury, stroke, burns, heart disease, diabetes, osteoarthritis, and rheumatoid arthritis.

However, because human stem cells can be harvested from human embryos, there must be strict guidelines in place to prevent the unethical development, distribution, or use of the embryonic material.

The Honorable Mike Enzi April 28, 2005 Page 2

research or in the development of human medical therapies. This is due to the age of the cells, contamination, the out-dated scientific techniques that were in place at the time the cells were harvested, and because none of the 22 lines carry a genetic defect for many of the most serious genetic diseases. As long as the current stem cell plan is in place, scientists cannot make the promise of stem cell research a reality.

S. 471 would allow stem cell research to progress. It would effectively eliminate the current restriction that scientists use only existing stem cell lines and would allow federal funding for research on stem cells that are derived in the future from embryos in limited circumstances. In particular, scientists could only use cells from embryos that were created for the purposes of fertility treatment. In addition, the embryo in question could only be used if it would otherwise have been discarded, and it can only be donated by the persons receiving fertility treatment without compensation and with full knowledge of how the cells will be used. These restrictions are essential to protect against the many potential abuses in embryo development and distribution.

We believe that stem cell research must go forward, but only if we can ensure that it goes forward responsibly and with adequate safeguards. S. 471 meets this standard. On behalf of the more than 23,000 members of the Association of the Bar of New York City, I would like to thank you for your attention to this important matter and urge you to ensure prompt passage of this significant legislation.

Very truly yours,

John Siff Chair

cc: Betsy Plevan, President
Barbara Berger Opotowsky, Executive Director
Alan Rothstein, General Counsel

COMMITTEE ON FEDERAL LEGISLATION

JOHN S. SIFFERT CHAIR 500 FIFTH AVENUE, FLOOR 33 NEW YORK, NY 10110 (212) 921-8399 FAX # (212) 764-3701 jsiffert@lswlaw.com

April 28, 2005

JOHN P. COLLINS, JR.

SECRETARY

300 QUARROPAS STREET, FLOOR 3

WHITE PLAINS, NY 10601

(914) 993-1919

FAX # (914) 993-1980

john.collins@usdoj.goy

VIA TELECOPIER – (202) 228-1264 <u>CONFIRMATION COPY BY MAIL</u>

The Honorable Bill Frist, M.D. Majority Leader United States Senate 509 Hart Senate Office Building Washington, DC 20510

Re: S. 471. The Stem Cell Research Enhancement Act of 2005

Dear Senator Frist:

We write on behalf of the Association of the Bar of the City of New York ("Association of the Bar") to express our strong support for S. 471, the Stem Cell Research Enhancement Act of 2005. S. 471 appropriately expands federal support for stem cell research beyond the current federal stem cell research program, and sets strict, but workable, standards to guard against the misuse of human embryonic materials.

Stem cell research holds enormous promise as scientists work to unravel the mysteries of human development and find cures to many devastating illnesses. According to the National Institutes of Health, human stem cells have the potential to treat patients who would now need an organ transplant, as well as those suffering from diseases including Parkinson's and Alzheimer's diseases, spinal cord injury, stroke, burns, heart disease, diabetes, osteoarthritis, and rheumatoid arthritis.

However, because human stem cells can be harvested from human embryos, there must be strict guidelines in place to prevent the unethical development, distribution, or use of the embryonic material.

The Honorable Bill Frist, M.D. April 28, 2005 Page 2

research or in the development of human medical therapies. This is due to the age of the cells, contamination, the out-dated scientific techniques that were in place at the time the cells were harvested, and because none of the 22 lines carry a genetic defect for many of the most serious genetic diseases. As long as the current stem cell plan is in place, scientists cannot make the promise of stem cell research a reality.

S. 471would allow stem cell research to progress. It would effectively eliminate the current restriction that scientists use only existing stem cell lines and would allow federal funding for research on stem cells that are derived in the future from embryos in limited circumstances. In particular, scientists could only use cells from embryos that were created for the purposes of fertility treatment. In addition, the embryo in question could only be used if it would otherwise have been discarded, and it can only be donated by the persons receiving fertility treatment without compensation and with full knowledge of how the cells will be used. These restrictions are essential to protect against the many potential abuses in embryo development and distribution.

We believe that stem cell research must go forward, but only if we can ensure that it goes forward responsibly and with adequate safeguards. S. 471 meets this standard. On behalf of the more than 23,000 members of the Association of the Bar of New York City, I would like to thank you for your attention to this important matter and urge you to ensure prompt passage of this significant legislation.

John Siffert

Chair

cc: Betsy Plevan, President
Barbara Berger Opotowsky, Executive Director
Alan Rothstein, General Counsel

COMMITTEE ON FEDERAL LEGISLATION

JOHN S. SIFFERT CHAIR 500 FIFTH AVENUE, FLOOR 33 NEW YORK, NY 10110 (212) 921-8399 FAX # (212) 764-3701 isiffert@lswlaw.com

April 28, 2005

JOHN P. COLLINS, JR.

SECRETARY

300 QUARROPAS STREET, FLOOR 3

WHITE PLAINS, NY 10601

(914) 993-1919

FAX # (914) 993-1980

john.collins@usdoj.gov

VIA TELECOPIER – (202) 224-7327 <u>CONFIRMATION COPY BY MAIL</u>

Senator Harry Reid Minority Leader United States Senate 528 Hart Senate Office Building Washington, DC 20510

Re: S. 471. The Stem Cell Research Enhancement Act of 2005

Dear Senator Reid:

We write on behalf of the Association of the Bar of the City of New York ("Association of the Bar") to express our strong support for S. 471, the Stem Cell Research Enhancement Act of 2005. S. 471 appropriately expands federal support for stem cell research beyond the current federal stem cell research program, and sets strict, but workable, standards to guard against the misuse of human embryonic materials.

Stem cell research holds enormous promise as scientists work to unravel the mysteries of human development and find cures to many devastating illnesses. According to the National Institutes of Health, human stem cells have the potential to treat patients who would now need an organ transplant, as well as those suffering from diseases including Parkinson's and Alzheimer's diseases, spinal cord injury, stroke, burns, heart disease, diabetes, osteoarthritis, and rheumatoid arthritis.

However, because human stem cells can be harvested from human embryos, there must be strict guidelines in place to prevent the unethical development, distribution, or use of the embryonic material.

Senator Harry Reid April 28, 2005 Page 2

research or in the development of human medical therapies. This is due to the age of the cells, contamination, the out-dated scientific techniques that were in place at the time the cells were harvested, and because none of the 22 lines carry a genetic defect for many of the most serious genetic diseases. As long as the current stem cell plan is in place, scientists cannot make the promise of stem cell research a reality.

S. 471would allow stem cell research to progress. It would effectively eliminate the current restriction that scientists use only existing stem cell lines and would allow federal funding for research on stem cells that are derived in the future from embryos in limited circumstances. In particular, scientists could only use cells from embryos that were created for the purposes of fertility treatment. In addition, the embryo in question could only be used if it would otherwise have been discarded, and it can only be donated by the persons receiving fertility treatment without compensation and with full knowledge of how the cells will be used. These restrictions are essential to protect against the many potential abuses in embryo development and distribution.

We believe that stem cell research must go forward, but only if we can ensure that it goes forward responsibly and with adequate safeguards. S. 471 meets this standard. On behalf of the more than 23,000 members of the Association of the Bar of New York City, I would like to thank you for your attention to this important matter and urge you to ensure prompt passage of this significant legislation.

Very truly yours,

Jbhn/Sif. Chair

cc:

Betsy Plevan, President Barbara Berger Opotowsky, Executive Director Alan Rothstein, General Counsel

COMMITTEE ON FEDERAL LEGISLATION

JOHN S. SIFFERT CHAIR 500 FIFTH AVENUE, FLOOR 33 NEW YORK, NY 10110 (212) 921-8399 FAX # (212) 764-3701 isiffert@lswlaw.com

April 28, 2005

JOHN P. COLLINS, JR.
SECRETARY
300 QUARROPAS STREET, FLOOR 3
WHITE PLAINS, NY 10601
(914) 993-1919
FAX # (914) 993-1980
john.collins@usdoj.gov

VIA TELECOPIER – (202) 228-5787 CONFIRMATION COPY BY MAIL

Senator Edward Kennedy Ranking Member Senate Committee on Health, Education, Labor & Pensions 315 Russell Senate Office Building Washington, DC 20510

Re: S. 471. The Stem Cell Research Enhancement Act of 2005

Dear Senator Kennedy:

We write on behalf of the Association of the Bar of the City of New York ("Association of the Bar") to express our strong support for S. 471, the Stem Cell Research Enhancement Act of 2005. S. 471 appropriately expands federal support for stem cell research beyond the current federal stem cell research program, and sets strict, but workable, standards to guard against the misuse of human embryonic materials.

Stem cell research holds enormous promise as scientists work to unravel the mysteries of human development and find cures to many devastating illnesses. According to the National Institutes of Health, human stem cells have the potential to treat patients who would now need an organ transplant, as well as those suffering from diseases including Parkinson's and Alzheimer's diseases, spinal cord injury, stroke, burns, heart disease, diabetes, osteoarthritis, and rheumatoid arthritis.

However, because human stem cells can be harvested from human embryos, there must be strict guidelines in place to prevent the unethical development, distribution, or use of the embryonic material.

Senator Edward Kennedy April 28, 2005 Page 2

research or in the development of human medical therapies. This is due to the age of the cells, contamination, the out-dated scientific techniques that were in place at the time the cells were harvested, and because none of the 22 lines carry a genetic defect for many of the most serious genetic diseases. As long as the current stem cell plan is in place, scientists cannot make the promise of stem cell research a reality.

S. 471 would allow stem cell research to progress. It would effectively eliminate the current restriction that scientists use only existing stem cell lines and would allow federal funding for research on stem cells that are derived in the future from embryos in limited circumstances. In particular, scientists could only use cells from embryos that were created for the purposes of fertility treatment. In addition, the embryo in question could only be used if it would otherwise have been discarded, and it can only be donated by the persons receiving fertility treatment without compensation and with full knowledge of how the cells will be used. These restrictions are essential to protect against the many potential abuses in embryo development and distribution.

We believe that stem cell research must go forward, but only if we can ensure that it goes forward responsibly and with adequate safeguards. S. 471 meets this standard. On behalf of the more than 23,000 members of the Association of the Bar of New York City, I would like to thank you for your attention to this important matter and urge you to ensure prompt passage of this significant legislation.

Very truly yours.

Chair

cc: Betsy Plevan, President
Barbara Berger Opotowsky, Executive Director
Alan Rothstein, General Counsel

COMMITTEE ON FEDERAL LEGISLATION

JOHN S. SIFFERT
CHAIR
500 FIFTH AVENUE, FLOOR 33
NEW YORK, NY 10110
(212) 921-8399
FAX # (212) 764-3701
jsiffert@lswlaw.com

April 28, 2005

JOHN P. COLLINS, JR.

SECRETARY

300 QUARROPAS STREET, FLOOR 3

WHITE PLAINS, NY 10601

(914) 993-1919

FAX # (914) 993-1980

john.collins@usdoj.gov

VIA TELECOPIER – (617) 565-3183 <u>CONFIRMATION COPY BY MAIL</u>

Senator Edward Kennedy Ranking Member Senate Committee on Health, Education, Labor & Pensions 2400 JFK Building Boston, MA 02203

Re: S. 471. The Stem Cell Research Enhancement Act of 2005

Dear Senator Kennedy:

We write on behalf of the Association of the Bar of the City of New York ("Association of the Bar") to express our strong support for S. 471, the Stem Cell Research Enhancement Act of 2005. S. 471 appropriately expands federal support for stem cell research beyond the current federal stem cell research program, and sets strict, but workable, standards to guard against the misuse of human embryonic materials.

Stem cell research holds enormous promise as scientists work to unravel the mysteries of human development and find cures to many devastating illnesses. According to the National Institutes of Health, human stem cells have the potential to treat patients who would now need an organ transplant, as well as those suffering from diseases including Parkinson's and Alzheimer's diseases, spinal cord injury, stroke, burns, heart disease, diabetes, osteoarthritis, and rheumatoid arthritis.

However, because human stem cells can be harvested from human embryos, there must be strict guidelines in place to prevent the unethical development, distribution, or use of the embryonic material.

Senator Edward Kennedy April 28, 2005 Page 2

research or in the development of human medical therapies. This is due to the age of the cells, contamination, the out-dated scientific techniques that were in place at the time the cells were harvested, and because none of the 22 lines carry a genetic defect for many of the most serious genetic diseases. As long as the current stem cell plan is in place, scientists cannot make the promise of stem cell research a reality.

S. 471would allow stem cell research to progress. It would effectively eliminate the current restriction that scientists use only existing stem cell lines and would allow federal funding for research on stem cells that are derived in the future from embryos in limited circumstances. In particular, scientists could only use cells from embryos that were created for the purposes of fertility treatment. In addition, the embryo in question could only be used if it would otherwise have been discarded, and it can only be donated by the persons receiving fertility treatment without compensation and with full knowledge of how the cells will be used. These restrictions are essential to protect against the many potential abuses in embryo development and distribution.

We believe that stem cell research must go forward, but only if we can ensure that it goes forward responsibly and with adequate safeguards. S. 471 meets this standard. On behalf of the more than 23,000 members of the Association of the Bar of New York City, I would like to thank you for your attention to this important matter and urge you to ensure prompt passage of this significant legislation.

Very truly yours,

John Siffert Chair

cc: Betsy Plevan, President

Barbara Berger Opotowsky, Executive Director

Alan Rothstein, General Counsel